Bainbridge-Ropers syndrome is a genetic syndrome caused by heterozygous loss-of-function pathogenic variants in ASXL3, which encodes a protein involved in transcriptional regulation.
Introduction
Bainbridge-Ropers syndrome (OMIM 615485) is caused by de novo heterozygous truncating pathogenic variants in ASXL3 (OMIM 615115) (Bainbridge et al., 2013) , a gene encoding a sex comb-like protein that plays a role in transcriptional regulation (Katoh and Katoh, 2004; Srivastava et al., 2016) . The clinical phenotype most commonly involves severe intellectual disability, speech difficulties, autistic features, hypotonia, dysmorphic features and early feeding difficulties. Of 28 published patients, seizures were reported in 9 (Bainbridge et al., 2013; Balasubramanian et al., 2017; Contreras-Capetillo et al., 2017; Dinwiddie et al., 2013; Hori et al., 2016; Kuechler et al., 2017; Srivastava et al., 2016) . Although seizures occur in ~1/3 of Bainbridge-Ropers cases, the epileptology has not yet been thoroughly characterized.
Here, we investigated the epilepsy phenotype in Bainbridge-Ropers syndrome. We report 3 patients with novel ASXL3 pathogenic variants and seizures, as well as additional epileptology data on 5 previously published individuals.
Methods
We were referred a patient with Bainbridge-Ropers syndrome, and performed electroclinical epilepsy phenotyping. This study was approved by the Human Research Ethics Committee of Austin Health, Project No. H2007/02961. Informed, written consent was obtained from the subject's parents.
We reviewed clinical and molecular genetic data available on patients reported in the DECIPHER database (https://decipher.sanger.ac.uk) with ASXL3 pathogenic variants and 4 seizures (Firth et al., 2009) , and obtained additional clinical data from submitting clinicians. We reviewed the literature regarding seizures in Bainbridge-Ropers syndrome, and obtained additional clinical data from patients with seizures reported in a 12-patient cohort (Balasubramanian et al., 2017) .
This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk. Funding for the DECIPHER project was provided by the Wellcome Trust.
Results

Patient #1:
A 6-year-old boy was referred with uncontrolled epilepsy and Bainbridge-Ropers syndrome with novel NM_030632.1:c.3106C>T, p.Arg1036* ASXL3 variant identified on singleton whole exome sequencing. The variant was considered pathogenic, predicted to result in premature protein truncation, and not present in the Genome Aggregation Database (gnomAD) or other population databases (Lek et al., 2016) . Sanger sequencing of this variant in both parents confirmed the variant was de novo.
His first seizure was afebrile generalized tonic-clonic status epilepticus at age two years.
Valproate was started and he was seizure-free for 18 months, at which time medication was weaned. He had a brief, self-limited generalized tonic-clonic seizure at 4.5 years, but medication was not re-started.
At 5.5 years, he began to have paroxysmal episodes of impaired awareness and loss of tone (Video). With these events, his parents first noticed decreased awareness, sometimes with dysconjugate gaze, and he appeared to hold his breath. He then had slow loss of tone, fell to the floor, and injured himself with more severe episodes. The duration of events was < 30 seconds, and he had up to 40 events in a day. The frequency of events did not noticeably change with reintroduction of valproate, or initiation of clobazam and lamotrigine.
His awake interictal EEG showed normal background with no epileptiform discharges, though occipital intermittent rhythmic delta activity (OIRDA) was often seen ( Figure A) . The ictal recording during his impaired awareness events initially showed bilateral posterior rhythmic delta activity, which often evolved into 5-10 seconds of rhythmic bifrontal sharp-slow discharges ( Figure B ). Based on the clinical manifestations and EEG correlate, the events were classified as atypical absence seizures. Ethosuximide was started and the frequency of events decreased considerably.
He had generalized hypotonia and severe developmental impairment from the first year of life.
He crawled at 18 months, walked independently at 4 years, and at 6 years, had no spoken words.
His only episode of regression came at 5.5 years with his onset of frequent seizures. There were no autistic features. He had hypotonic facies with peri-orbital fullness, full cheeks, an open mouth with drooling and a thick lower vermillion, and small ears. Table ( patients #2, 3). Both patients had generalized tonic-clonic seizures alone and phenotypes consistent with childhood-onset generalized epilepsy.
Patient #2:
A 17-year-old male was evaluated at 3 months, for poor feeding, visual inattention, failure to thrive and possible seizures. Subsequently, he developed spasticity affecting his lower limbs, nystagmus, scoliosis, and multiple contractures of upper and lower limbs. He required surgical decompression for an ulnar nerve compression. His height, weight and head circumference were < 0.4th centile and he had severe global developmental impairment and was non-verbal.
In early childhood, he was investigated for stimulus-sensitive shuddering episodes with eyelid flickering, usually associated with excitement or with auditory or visual stimulation. An EEG showed generalised spike-wave discharges with photosensitivity. However, a trial of valproate resulted in overall deterioration in his behaviour, did not modify the shaking episodes, and was discontinued. Subsequent EEG telemetry captured the episodes of shaking, and suggested the events were unlikely to be epileptic. At 13 years, he presented with two episodes in a 24-hour period consistent with generalised tonic-clonic seizures, occurring during a wean of codeine 7 prescribed to manage generalised pain symptoms. He was commenced on lamotrigine and remained seizure-free until 16 years when he had a further episode during sleep that was thought to be a seizure. Subsequent concerns that the lamotrigine was affecting his mood led to a change to levetiracetam, discontinued at 18 years. He remained seizure-free at last assessment.
Whole exome sequencing identified a de novo ASXL3 splice site variant (NM_030632.2:c.3039+1G>A), not present in gnomAD, and predicted to severely decrease splice signal based on the in silico tool, MaxEntScan (Yeo and Burge, 2004) .
Patient #3:
A 7-year-old boy had mild global developmental impairment and autism spectrum disorder. He presented with prolonged generalized tonic-clonic seizures, including status epilepticus, at 4 years. Seizures typically occurred every 4-6 months. Valproate was initiated and reduced seizure frequency. His physical examination was notable for borderline microcephaly, with height and weight at ~90 th percentile, and head circumference the 2 nd .
Whole exome sequencing identified a de novo ASXL3 loss-of-function variant (NM_030632.2:c.3313_3316delCAGA, p.Thr1106ArgfsTer36), not present in gnomAD.
Previously Published Cases
In the 12-patient cohort of Balasubramanian et al, one additional patient has experienced seizures in addition to the four noted in the original table. The available clinical data are summarized in 
Conclusions
We present three patients with Bainbridge-Ropers syndrome, all of whom have generalized epilepsy with childhood-onset generalized tonic-clonic seizures. Patient #1 also had unusual absence seizures, involving altered patterns of breathing that could be mistaken for breathholding or hyperventilation events. Although detailed epilepsy phenotyping was not available for the patients published in the Balasubramanian cohort, the available data is also consistent with generalized epilepsy with generalized tonic-clonic and/or absence seizures. These findings indicate that the typical epilepsy phenotype in Bainbridge-Ropers syndrome is childhood-onset generalized epilepsy with absence and generalized tonic-clonic seizures.
Understanding the epileptology of Bainbridge-Ropers syndrome is of clinical importance, as ASXL3 variation was frequently identified in a trio whole exome sequencing study of children with non-specific intellectual disability (Balasubramanian et al., 2017; Wright et al., 2015) . A better knowledge of the typical epilepsy presentation and course will inform diagnosis, counseling and treatment decisions.
From a molecular genetic perspective, we present the first patient with a de novo splice site variant, as the cause of the patient's severe developmental impairment and epilepsy. All previous cases of Bainbridge-Ropers syndrome have occurred with variants leading to premature protein truncation, as was the case with our patients #1 and 3 (Balasubramanian et al., 2017) .
The observation of generalized epilepsy in Bainbridge-Ropers syndrome has important implications for our understanding of the underlying pathophysiology of this disorder. The disrupted protein, ASXL3, is involved in transcriptional regulation (Katoh and Katoh, 2004; Srivastava et al., 2016) , and the recognition of the epilepsy phenotype may give clues as to which downstream pathways are disrupted. The genes implicated in the generalized epilepsies are primarily related to ion channels and neurotransmitter receptors, such as sodium channels and GABA receptors (Helbig, 2015) , and it may be that altered transcriptional regulation with ASXL3 dysfunction leads to disruption of these proteins. There is initial rhythmic delta activity over the posterior head regions, which evolves into 6-7 seconds of slow spike-wave (~1.25 Hz) rhythmic discharges which are maximal over the frontal regions.
